Oncology & Cancer
Adipose tissue may affect cancer development in multiple ways
Adipose tissue, or fat, may influence the development of cancer in diverse ways, depending on the type of fat and the location in the body.
Sep 1, 2017
0
2
American Association for Cancer Research
Oncology & Cancer
Sorafenib effective in patients with non-small cell lung cancer, but low survival rates reported
Sorafenib was effective in patients with non-small cell lung cancer and a KRAS mutation, but survival rates were reportedly "unsatisfactory," according to data presented at the AACR-IASLC Joint Conference on Molecular Origins ...
Jan 10, 2012
0
0
Oncology & Cancer
Peptide vaccine shows evidence of immunological, clinical activity in children with gliomas
Peptide vaccination in children with gliomas was well tolerated with evidence of immunological and clinical responses, but some children experienced periods of immunological pseudoprogression, where tumors appeared larger ...
Apr 3, 2012
0
0
Oncology & Cancer
KRAS G12C inhibitor sotorasib may offer long-term clinical benefit in patients with non-small cell lung cancer
Patients with non-small cell lung cancer (NSCLC) treated with the KRAS G12C inhibitor sotorasib (Lumakras) had a two-year overall survival rate of 32.5 percent, according to data from the CodeBreaK 100 clinical trial presented ...
Apr 10, 2022
0
8
Medications
Combinatorial therapy shows early promise in patients with relapsed small cell lung cancer
The PARP inhibitor olaparib (Lynparza) in combination with the chemotherapeutic agent temozolomide (Temodar) showed clinical efficacy in patients with relapsed small cell lung cancer (SCLC), according to results from a phase ...
Aug 16, 2019
0
2
Oncology & Cancer
Study identifies potential drug combination for mantle cell lymphoma and chronic lymphocytic leukemia
Using the molecularly targeted drug ibrutinib (Imbruvica) together with the investigational anticancer agent ABT-199 may improve outcomes for patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL), ...
Sep 23, 2014
0
0
Oncology & Cancer
AKT inhibitor AZD5363 well tolerated, yielded partial response in patients with advanced solid tumors
The investigational drug AZD5363, which has shown activity in preclinical studies, was well tolerated in humans, and two patients with advanced solid tumors showed partial response, according to data presented at the AACR ...
Apr 8, 2013
0
0
Oncology & Cancer
PARP inhibitors may have clinical utility in HER2-positive breast cancers
Poly (ADP-Ribose) polymerase (PARP) inhibitors, shown to have clinical activity when used alone in women with familial breast and ovarian cancers linked to BRCA mutations, may be a novel treatment strategy in women with HER2-positive ...
Sep 17, 2012
0
0
Oncology & Cancer
Patient-partnered genomics study IDs immunotherapy as potential treatment for rare cancer
Angiosarcoma Project, a patient-partnered genomics study, identified immune checkpoint inhibition as a potential treatment option for patients with angiosarcomas of the head, face, neck, or scalp (HFNS), according to data ...
Sep 30, 2018
0
17
Oncology & Cancer
Epigenetic therapy shows promise in hard-to-treat lung cancer
Patients with recurrent metastatic non-small cell lung cancer have a morbid prognosis, but a new epigenetic therapy may have potential for this population, according to data published in Cancer Discovery, a journal of the ...
Nov 10, 2011
0
0
